id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-301946-erzh30mt	Kwak-Kim, Joanne	COVID-19 and immunomodulation treatment for women with reproductive failures	2020-06-12		.txt	text/plain	5604	335	42	With the Coronavirus Disease 2019 (COVID-19) pandemic, patient care has been significantly challenged not only for the COVID-19 cases but for the others, including pregnant women with a history of reproductive failures (RF), such as recurrent pregnancy losses (RPL), repeated implantation failures (RIF), with immune etiologies including autoimmune diseases, cellular immune dysfunction, and rheumatic conditions. SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus), which caused the SARS outbreak in 2003, infects macrophages and T cells (Perlman and Dandekar 2005) and induces various cytokines, such as type I IFN, TNF-α, IL-1, etc., and B cell-related antibodies (Prompetchara et al. With the currently available data, it is unlikely that the use of IVIg in patients with RFI will impact the chances of contracting the disease or negatively affect the clinical course in women with COVID-19 infection during pregnancy.	./cache/cord-301946-erzh30mt.txt	./txt/cord-301946-erzh30mt.txt